B
FULC icon

Braidwell’s Fulcrum Therapeutics FULC Stock Holding History

Braidwell’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24M Buy
3,134,922
+73,700
+2% +$684K 0.8% 49
2025
Q4 		$34.6M Buy
3,061,222
+2,841,734
+1,295% +$28.9M 1.11% 37
2025
Q3 		$2.02M Buy
+219,488
New +$1.59M 0.06% 70
2024
Q4 		– Sell
-1,069,158
Closed -$3.82M – 82
2024
Q3 		$3.82M Buy
+1,069,158
New +$7.93M 0.11% 75

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Braidwell's FULC Position: Q1 2026 in Review

Braidwell increased its Fulcrum Therapeutics (FULC) stake by 2.4% in Q1 2026, buying an estimated $684K and bringing the position to 3,134,922 shares worth $24M. The position accounts for 0.8% of the portfolio, ranked #49.

Braidwell first reported a position in FULC in Q3 2024 and has held it in 4 quarters since. The position peaked at $34.6M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Braidwell held 3,134,922 shares of Fulcrum Therapeutics worth $24M as of Q1 2026.
  • Braidwell bought 73,700 Fulcrum Therapeutics shares in Q1 2026, an estimated $684K.
  • Fulcrum Therapeutics made up 0.8% of Braidwell's portfolio in Q1 2026, its #49 holding.
  • Braidwell first reported a position in Fulcrum Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Braidwell's Fulcrum Therapeutics position peaked at $34.6M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.